Assessing Patient Organization Participation in Health

Policy: A Comparative Study in France and Italy by Souliotis, Kyriakos et al.
Assessing Patient Organization Participation in Health 
Policy: A Comparative Study in France and Italy
Kyriakos Souliotis1*, Eirini Agapidaki1, Lily Evangelia Peppou2, Chara Tzavara1, Dimitrios Varvaras3, 
Oreste Claudio Buonomo3, Dominique Debiais4, Stanimir Hasurdjiev5, Francois Sarkozy6
Abstract
Background: Even though there are many patient organizations across Europe, their role in impacting health policy 
decisions and reforms has not been well documented. In line with this, the present study endeavours to fill this gap in the 
international literature. To this end, it aims to validate further a previously developed instrument (the Health Democracy 
Index - HDI) measuring patient organization participation in health policy decision-making. In addition, by utilizing this 
tool, it aims to provide a snapshot of the degree and impact of cancer patient organization (CPO) participation in Italy 
and France. 
Methods: A convenient sample of 188 members of CPOs participated in the study (95 respondents from 10 CPOs in Italy 
and 93 from 12 CPOs in France). Participants completed online a self-reported questionnaire, encompassing the 9-item 
index and questions enquiring about the type and impact of participation in various facets of health policy decision-
making. The psychometric properties of the scale were explored by performing factor analysis (construct validity) and by 
computing Cronbach α (internal consistency). 
Results: Findings indicate that the index has good internal consistency and the construct it taps is unidimensional. The 
degree and impact of CPO participation in health policy decision-making were found to be low in both countries; however 
in Italy they were comparatively lower than in France. 
Conclusion: In conclusion, the HDI can be effectively used in international policy and research contexts. CPOs 
participation is low in Italy and France and concerted efforts should be made on upgrading their role in health policy 
decision-making. 
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Implications for policy makers
• The first step to ensure patients’ participation in shaping health policies is the development and enforcement of relevant legislation.
• The main barriers preventing patients to participate in health and healthcare decisions are: limited knowledge about cancer, the health system 
and health policies as well as lack of lobbying and advocacy skills. Targeted interventions on these topics would be beneficial in increasing 
patient participation in every aspect of decision-making.
• Policy-makers should invest in regulations that focus on equal and meaningful participation of patient groups in health policy decision-making. 
To this end, they should develop online informational and monitoring systems.
• The Health Democracy Index (HDI) is a brief and robust tool which can be used to assess the degree and impact of patients’ organization 
participation in health policy decision-making.
Implications for the public
Patient organization participation allows patients to be an integral part of the health policy decision-making course that influences their health. 
In recent years, patient organizations have the role of representing groups of patients at various levels (eg, local, national, international). The main 
objective of patient organizations is not only to participate but also to influence health policy decisions. Evidence from the present study suggests that 
even though there are cancer patient organizations (CPOs) in Italy and France, they fail to participate successfully in health policy decision-making 
processes and influence them effectively. Consistent efforts should be made on the part of citizens, patients and their representatives on acquiring a 
central position in health policy decision-making.
Key Messages 
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Introduction
Patient participation is a multidimensional concept originating 
from the widespread consumer movement in 1960’s, which 
was centered on consumers’ right to safety, to be informed, 
to choose and to be heard.1 Nonetheless, the concept is 
considered ill-defined due to diversity of its applicability2 
and various terms, such as patient collaboration, patient 
involvement, partnership, patient empowerment or patient-
centered care, have been used interchangeably in existing 
literature.2 Moreover, patient participation pertains to a 
wide range of healthcare aspects, such as decision-making, 
self-medication, self-monitoring, patient education and goal 
setting, among others. In this rationale, patient participation 
is conceptualised as the process that allows patients to be an 
integral part of the decision-making course that influences 
their health.3,4 Congruent with this, they can contribute to a 
wide range of activities from formulating treatment plans to 
shaping germane policies. 
Patient participation in developing health policies refers 
to individuals’ involvement in every step of planning, 
development and implementation of healthcare programs, 
interventions and services.5,6 This approach implies that 
patient participation may occur on various levels: (i) the 
individual or micro level, wherein the patient participates as 
a member of the healthcare team in decisions that directly 
affect his/her health (eg, clinical decision-making); (ii) the 
meso level, which refers to engagement in health decision-
making on a local or organizational level (eg, local health 
authorities and/or hospital organizations), and (iii) the 
macro level, which involves participation in health issues on 
a federal, national or international level.7-10 The importance of 
patient involvement in every stage of the healthcare process 
has been substantiated.11,12 There are 2 lines of argumentation 
justifying patient organization participation in health policy 
decision-making. The first is political and stems from the 
democratic values of transparency and accountability13; the 
second is health-related and derives from the principle of 
equity and the health promotion approach.14 Patients are 
supported to increase the control over the factors which 
influence their health and become more active in the 
development, planning, delivery and evaluation of health 
services.15 Indeed, existing research indicates that increased 
patient participation is linked to enhanced quality of 
healthcare services, elevated effectiveness and efficiency of 
health systems and better population health outcomes.16-19 
On the other hand the sustainability and effectiveness of the 
healthcare systems is threatened due to the high prevalence 
of the non-communicable diseases (NCDs) worldwide. The 
high prevalence of NCDs has resulted in growing demands 
and costs due to the manifold impact of chronic illnesses on 
health and healthcare.20,21 Patient participation may contribute 
to a more effective allocation of resources so as to ensure that 
effective and sustainable health services will be provided. 
As a corollary of this, a lot of programs have been implemented 
internationally, geared towards raising patients’ awareness 
and empowerment. In this way, patients may participate more 
actively and effectively in health decision-making processes. 
These initiatives have largely focused on improving health 
literacy, enhancing patient involvement in treatment decision-
making and fostering self-management support. Consistent 
with this, treatment options become individualized and 
tailored to a patient’s profile, strengthening therefore his 
or her motivation.10,22-25 Since the primary goal of these 
programs is to achieve changes on the micro-level, the main 
research activity is concentrated on the micro-level. On the 
other hand, initiatives at meso and macro levels are scarce and 
essentially serve advocacy purposes.26-28 
Similarly, although there are instruments, albeit poorly 
validated,29 assessing patient participation on the micro-level, 
there is a paucity of tools for gauging the degree of patient 
participation on the meso and macro level.10,17,29 
Patients suffering from chronic diseases usually seek 
additional information and social support in several formal 
and informal patient organization groups. There are different 
types of patient groups and networks, targeting a diversity 
of patient needs.30 For instance, many cancer patients seek 
social support in groups created so as to strengthen the social 
network of cancer patients and to empower their caregivers31; 
while others prefer to join a formal cancer patient organization 
(CPO) to acquire more information about the healthcare 
system and the reimbursement processes. In the second case, 
patients become familiar with health policy strategies and 
processes in the majority of instances.32 Thereby, patients 
advance their understanding about health policy decision- 
making and thus claim equal participation.33 Even though 
there are many patient organizations across Europe, their role 
in impacting health policy decisions and reforms has not been 
well documented.34
The limited number of qualitative studies in the field emanate 
predominantly from the United Kingdom, the United States, 
Germany and the Netherlands.30,35-38 Converging evidence 
from these countries substantiates a proliferation of patient 
organizations during the past decades and increased contacts 
between patient groups and policy-makers.30,35-38 In fact, 
Allsop and colleagues report that professionals bodies and 
pharmaceutical companies have increasingly included 
patient groups in discussions on policy proposals in the 
United Kingdom.38 Nonetheless, the growing participation 
of patient groups in health policy does not necessarily lead 
to their political effectiveness, with some authors arguing 
that it constitutes mere incorporation rather than effective 
participation.38 Similarly, research in the Netherlands 
indicates that while the system provides many opportunities 
for patient organizations to participate, patient groups often 
lack the resources or/and the expertise to meet pertinent 
demands.30 As a corollary of this, they cannot be an equal 
party in health policy process. This strand of research provides 
very valuable insights into patient groups and their political 
effectiveness in these countries; however, these studies have 
primarily employed qualitative methodology to meet their 
research aims. Up to date, no quantitative study has taken 
place to explore patient organization participation in health 
policy in 2 European countries. The aim of the present study 
is to fill this gap in the international literature, by exploring 
the influence of CPOs in health policy-decision-making in 2 
European countries.
The reason for concentrating on cancer rather than on other 
chronic or debilitating health conditions pertains to evidence 
suggesting that cancer remains a key public health concern, 
incurring substantial burden to European societies.39 In 
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particular, it constitutes one of the main causes of morbidity 
and mortality worldwide, while the cost of treatment remains 
high.40 There is also a large body of literature corroborating an 
association between inequalities in accessing cancer treatment 
and elevated risk of mortality41,42; while overcoming barriers 
to cancer treatment is top priority.41 In line with these, CPOs 
may play a prominent role in facilitating removal of these 
barriers, advocating patients’ rights and influencing germane 
policies. 
Consistent with the aforementioned, the present study has set 
out the following objectives:
(i) to validate further a previously developed instrument (the 
Health Democracy Index - HDI) for measuring CPO’s degree 
and impact of participation in health policy decision-making 
by utilizing this tool; 
(ii) to compare the degree and impact of CPOs in health 
policy in Italy and France.
A previous exploration of the HDI in a random sample of 
members of patient organizations in Greece indicated that 
the scale has good psychometric properties: construct and 
convergent validity, internal consistency and test-retest 
reliability.43 This is the first attempt to adapt the instrument to 
another language and culture. 
Methods
Instrument Adaptation
The HDI is an original scale consisting of 8 items, enquiring 
about patient organization participation in health policy 
decision processes at the meso- and macro-level: reforms, 
panels at the Ministry of Health, panels in other prominent 
health-related organizations, hospital boards, Ethics 
Committees in clinical trials, health technology assessment 
procedures and the national parliament. For each item, 7 
response options were provided: (i) it is not a legal requirement 
and it never happens, (ii) ) it is not a legal requirement and it 
rarely happens, (iii) it is not a legal requirement but it often 
happens, (iv) it is a legal requirement and it never happens, (v) 
it is a legal requirement and it often happens, (vi) it is a legal 
requirement and it happens very often, and (vii) it is a legal 
requirement and it always happens. In addition, there was one 
question enquiring about the frequency whereby a substantial 
change in a health policy decision was evoked as a result of 
the involvement of patient organization in the process. For 
this item, ratings were made on a 7-point scale reflecting a 
frequency dimension: never-very rarely-rarely-sometimes-
often-very often. Higher composite scores indicated higher 
levels of patient organisation participation. 
The development of the index43 followed the subsequent steps: 
(i) definition of the construct, (ii) review of the construct 
definition, (iii) item drafting, (iv) item review, and (v) pilot 
testing of its psychometric properties (reliability: internal 
consistency, test-retest reliability and validity: construct 
validity and convergent validity. Furthermore, weights were 
assigned to the items of the index by employing a Delphi 
methodology.
After the positive results of the pilot study,43 the research 
group started processing participants’ feedback on the 
instrument. Moreover, an international working group, 
consisting of European stakeholders (policy-makers, 
members of patient organizations and researchers with 
background in patient empowerment), held various meetings 
to discuss the adaptation of the index to European standards. 
As a corollary of these, it was decided to divide the item 
exploring health technology assessment procedures into 2 
components: scientific assessment and economic assessment, 
with an accompanying division of their weights as well. In 
this reasoning, the HDI became a 9-item index. For each of 
the nine questions of the HDI, one item enquiring about the 
type of patient organization participation and one concerning 
its impact were added. The type of patient participation was 
rated as “observer” (mere presence of the member/non-
voting), “consulting” (the member provides information 
and/or makes recommendations on a particular subject, 
non-voting), “vocal participant” (the member delivers a 
presentation and/or makes a speech, non-voting), “voting 
member.” The item capturing the impact of this participation 
was rated on a 6-point scale ranging from “absent” to “very 
high.”
Apart from the HDI, the research instrument encompassed 
the following sub-sections: respondents’ socio-demographic 
characteristics, respondents’ disease characteristics (eg, 
familiarity with disease, year of initial diagnosis, knowledge of 
treatment options), 4 items about the individual’s involvement 
in the patient organization (eg, position in the organization, 
years of membership, degree of personal involvement) and 
9 items assessing the degree of participation and impact of 
all patient organizations in the country (eg, the degree of 
participation/impact/collaboration of all patient organizations 
in health policy decision-making in the country). 
The instrument was translated and back-translated from 
Greek to English by 2 bilingual researchers. A similar process 
was then followed for translation and back translation from 
English to French and Italian. 
Sample and Procedure
A convenient sample of 188 patients-members of CPOs were 
included in the study. Potential participants were identified 
through contact with the CPOs. A CPO was defined as any 
patient group with a legal entity, (official associations), that 
focused on cancer. To be eligible for inclusion into the study, 
CPOs had to: (a) be active on a national level, (b) represent 
cancer patients, and (c) have an accessible website. 
A total of 43 CPOs, which fulfilled the inclusion criteria 
in France, and 27 in Italy were invited to participate in the 
study. Since an official list of European Union (EU) patient 
organizations does not exist and thus the number of CPOs 
in each country as well as the number of members of each 
CPO is inaccessible, we endeavoured to minimize selection 
bias by identifying eligible CPOs through different sources: 
online databases, registries of European websites relevant 
to cancer patient groups, lists belonging to the Ministry 
of Health, contacts with key persons in each country and 
European umbrella organizations. After contacts were made, 
10 CPOs in Italy (37%) and 12 in France (28%) agreed to 
take part. In Italy, 8 CPOs (30%) did not reply to repeated 
calls and emails of the research team and 9 (33%) refused to 
participate. Similarly, in France, 15 CPOs did not respond to 
the calls/emails (37%) and 16 (37%) refused to participate. 
Reasons for refusal include: they considered participation 
time consuming, other activities were in priority at the time, 
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the CPO was not particularly active during the past year 
and difficulties with the Review Board that had to approve 
the study protocol. Upon comparing CPOs that agreed to 
participate and those that did not, one may discern that the 
most visible and active CPOs participated. 
For the recruitment of potential participants, an email 
invitation was sent to the president or other contact person 
of the CPO. After initial acceptance of participation, the 
Institutional Review Board of each organization approved the 
study protocol. Data was collected online. Board members of 
each patient agency circulated an invitation for participation 
to all members of the organization. If a member agreed to 
participate and signed the written informed consent, the 
board members would forward the questionnaire either via 
email or a web-link. In order to be eligible for the study, 
patients should have been adult members of the CPO, with 
sufficient knowledge of Italian/French or English language. A 
total of 95 members from the 10 CPOs in Italy and 93 from 
the 12 CPOs in France provided complete data. Data were 
collected the time period January to February 2016. 
Sample characteristics can be found in Table 1. As shown 
in Table 1, no statistically significant differences emerged 
between respondents in Italy and France.
Statistical Analysis
Variables were firstly tested for normality using the 
Kolmogorov-Smirnov criterion. Variables with skewed 
distribution are presented with median and interquartile 
range (IQR). Categorical variables are presented with absolute 
and relative frequencies. For the comparisons of proportions, 
chi-square and Fisher exact tests were used were appropriate. 
Due to the lack of normality, the non-parametric Mann-
Whitney test was computed for the comparison of median 
values between 2 groups, as the distribution was not normal. 
Also, the non-parametric Kruskal-Wallis test was used for the 
comparison of median values between 3 or more groups. 
Exploratory factor analysis was carried out to evaluate 
construct validity of the HDI in the 2 samples and to 
determine whether the scale tapped a unidimensional 
construct. Principal component analysis (PCA) was chosen as 
extraction method using varimax rotation. The cut-off point 
for factor loadings was 0.4 and for eigenvalues it was 1.0. The 
internal consistency of the questionnaire was assessed with 
Cronbach α coefficient. Reliability equal to or greater than 
0.7 was considered acceptable. All P values reported are 
2-tailed. Statistical significance was set at .05 and analyses 
were conducted using SPSS statistical software (version 19.0).
Results
Psychometric Properties
The internal consistency of the HDI was considered adequate 
(Cronbach α = .93 in Italy and Cronbach α = .70 in France). 
PCA with a varimax rotation was used to explore the 
construct validity of the scale. One factor was revealed with 
eigenvalue more than one for both countries and accounted 
for 67.7% and 64.4% of the total variance in Italy and France 
respectively. All items were entered into the factor analysis 
and factor loadings ranged from 0.6 to 1.0. in Italian data and 
from 0.5 to 0.9 in French data.
Comparison of Italy and France
The medians of the HDI items are shown in Table 2. 
Significantly higher values were found for all of the HDI 
items in the French sample as compared to their Italian 
counterparts.
The type of participation (Table 3) was primarily “observer” in 
Italy, while it was “consulted” in France. As regards the “vocal 
participant” category, it was found to have significantly higher 
frequency in Italy with respect to participation in “reforms 
or key decisions in health policy” and “health technology 
assessment procedures for the economic evaluation of new 
treatments & methods” and significantly higher in France 
with regard to participation in “panels of experts or workshops 
held in the Ministry of Health,” “panels or workshops in other 
important organizations pertinent to health” and “Ethics 
Committees for clinical trials.”
The impact of participation was more frequently absent 
to low (Table 4). Additionally, it was higher in France than 
in Italy regarding the items “reforms or key decisions in 
health policy,” “panels of experts or workshops held in the 
Ministry of Health,” “panels or workshops in other important 
organizations pertinent to health,” “hospital boards,” and 
“Ethics Committees for clinical trials.”
In France, a statistically significant difference was 
documented in the HDI score among different levels of 
participants’ knowledge of treatment options and of their 
country’s healthcare system. Specifically, as shown in Table 
5, participants with very low to moderate knowledge about 
treatment options and about their country’s healthcare system 
had significantly lower HDI score. Moreover a statistical 
significant correlation was found between participants’ 
contention that there is a larger umbrella organization to 
represent all patients or different organizations in their 
country and lower HDI score. A greater HDI score was found 
in participants who believed that their patient organization 
was a member of an umbrella organization that represented 
them on a national policy decision-making. Furthermore, a 
significantly greater HDI score was observed in cases where 
participants reported that there is a collaboration between 
their association and other patient organizations on a national 
policy/decision-making level. 
In Italy, there was a significant difference in HDI score among 
different levels of participants’ knowledge about treatment 
options, their country’s healthcare system and their country’s 
drug reimbursement processes (Table 5). In particular, it was 
found that participants with very low to moderate knowledge 
about the aforementioned areas of knowledge had significantly 
lower HDI score. Furthermore, participants who reported 
“moderate to very high” degree of collaboration between their 
organization and other patient organization of the same or 
other disease area displayed significantly higher HDI score. 
Similarly, a greater HDI score was found when participants 
believed there is a larger umbrella organization to represent 
all patients or different organizations in their country as well 
as when they believed that their patient organization was a 
member of this umbrella organization.
Discussion
The present study aimed to validate further an original 
instrument for measuring patient organization participation 
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Table 1. Respondents’ Characteristics in France, Italy and the Sample as a Whole
Total Sample (N = 188) France (n = 93) Italy (n = 95)
P Valuea
No. (%) Mean (SD) Median (Min-Max) No. (%) Mean (SD) Median (Min-Max) No. (%) Mean (SD) Median (Min-Max)
Gender > .001
Male 64 (34.0) - - 31 (33.3) - - 33 (34.7) - -
Female 128 (66.0) - - 62 (66.7) - - 62 (65.3) - -
Educational level > .001
Νon formal qualification - - - - - - - - -
Primary school education (up to age 12) - - - - - - - - -
Secondary school education (up to age 15-16) - - - - - - - - -
Secondary school education (up to age 18) 80 (42.5) - - 40 (43.0) - - 40 (42.1) - -
University degree 42 (22.4) - - 21 (22.6) - - 21 (22.1) - -
Postgraduate degree 66 (35.1) - - 32 (34.4) - - 34 (35.8) - -
Age - 50.9 (7.7)  (26-67) - 51 (7.8) 54 (26-67) - 50.8 (7.7) 51 (32-60) > .001
Position in the organization > .001
President or other board member 35 (18.6) - - 17 (18.3) - - 18 (18.9) - -
Employed by the organization 43 (22.9) - - 22 (23.7) - - 21 (22.1) - -
Voting member 23 (12.2) - - 12 (12.9) - - 11 (11.6) - -
Non-voting but active member 50 (26.6) - - 24 (25.8) - - 26 (27.4) - -
Non-active member 37 (19.7) - - 18 (19.3) - - 19 (20.0) - -
Individuals’ personal involvement in the organization > .001
Νone 6 (3.2) - - 3 (3.2) - - 3 (3.3) - -
Very low 15 (8.0) - - 7 (7.6) - - 8 (8.4) - -
Low 40 (21.3) - - 20 (21.5) - - 20 (21.0) - -
Moderate 42 (22.3) - - 21 (22.6) - - 21 (22.1) - -
High 39 (20.7) - - 19 (20.4) - - 20 (21.0) - -
Very high 46 (24.5) - - 23 (24.7) - - 23 (24.2) - -
Membership duration (in years) - 4.4 (4.2) 4 (1-21) - 4.5 (3.9) 4 (1-17) - 4.4 (4.4) 4 (1-21) > .001
a P values correspond to comparisons between the samples in France and Italy.
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Table 2. Descriptive Statistics for the HDI Items and Comparison Between Italy and France
France Italy
Pa
Median (IQR) Median (IQR)
Does your patient organization participate:
In reforms or key decisions in health policy? 3 (2-3) 1 (1-2) < .001
In panels of experts or workshops held in the  Ministry of Health? 3 (2.5-3) 1 (1-3) < .001
In panels or workshops in other important organizations pertinent to health? 3 (2-3) 1 (1-2) < .001
In hospital boards? 2 (1-3) 1 (1-3) .040
In Ethics Committees for clinical trials? 3 (2-3) 1 (1-2) < .001
In health technology assessment procedures for the scientific evaluation of new treatments & methods? 2 (1-2) 1 (1-2) < .001
In health technology assessment procedures for the economic evaluation of new treatments & methods? 2 (1-2) 1 (1-1) < .001
In the national parliament during decision-making for important health policies/legislation? 2 (2-3) 1 (1-3) < .001
How often do you observe a substantial change in the content of a health policy decision as a result of the 
involvement of your patient organization?
3 (2-5) 3 (1-4) .009
HDI score (sum) 22 (20-27) 12 (9-17) < .001
HDI score (average) 2.4 (2.2-3) 1.3 (1-1.9) < .001
Abbreviations: HDI, Health Democracy Index; IQR, interquartile range.
a Mann-Whitney test.




 No. (%) No. (%) P
In reforms or key decisions in health policy
Observer 39 (41.9) 65 (68.4) < .001a
Consulted 45 (48.4) 5 (5.3)
Vocal participant 9 (9.7) 20 (21.1)
Voting member 0 (0.0) 5 (5.3)
In panels of experts or workshops held in the  Ministry of Health
Observer 21 (22.6) 85 (89.5) < .001b
Consulted 39 (41.9) 0 (0.0)
Vocal participant 33 (35.5) 10 (10.5)
Voting member 0 (0.0) 0 (0.0)
In panels or workshops in other important organizations pertinent 
to health
Observer 30 (32.3) 80 (84.2) < .001b
Consulted 42 (45.2) 0 (0.0)
Vocal participant 21 (22.6) 5 (5.3)
Voting member 0 (0.0) 10 (10.5)
In hospital boards
Observer 42 (45.2) 80 (84.2) < .001a
Consulted 39 (41.9) 0 (0.0)
Vocal participant 9 (9.7) 15 (15.8)
Voting member 3 (3.2) 0 (0.0)
In Ethics Committees for clinical trials
Observer 33 (35.5) 85 (89.5) < .001a
Consulted 27 (29.0) 0 (0.0)
Vocal participant 27 (29.0) 10 (10.5)
Voting member 6 (6.5) 0 (0.0)
In health technology assessment procedures for the scientific 
evaluation of new treatments & methods
Observer 60 (64.5) 80 (84.2) < .001a
Consulted 24 (25.8) 5 (5.3)
Vocal participant 6 (6.5) 10 (10.5)
Voting member 3 (3.2) 0 (0.0)
In health technology assessment procedures for the economic 
evaluation of new treatments & methods
Observer 78 (83.9) 80 (84.2) < .001a
Consulted 15 (16.1) 0 (0.0)
Vocal participant 0 (0.0) 10 (10.5)
Voting member 0 (0.0) 5 (5.3)
In the national parliament during decision-making for important 
health policies/legislation
Observer 63 (67.7) 80 (84.2) < .001a
Consulted 27 (29.0) 5 (5.3)
Vocal participant 3 (3.2) 5 (5.3)
Voting member 0 (0.0) 5 (5.3)
Abbreviation: HDI, Health Democracy Index.
a Fisher exact test; b Pearson chi-square test.
Souliotis et al
International Journal of Health Policy and Management, 2018, 7(1), 48–5854
of the index in Greece (Cronbach α = .85 ).31 Furthermore, 
findings from factor analysis revealed that the construct of 
patient organization participation tapped in the instrument 
is unidimensional. In this reasoning, the HDI continues 
to display good psychometric properties, when applied in 
different countries.
Concerning CPOs participation in health policy, the 
highest level of participation in France was observed with 
respect to reforms and key decisions in health policy, in 
panels/workshops help at the Ministry of Health, in panels/
workshops in other important health-related organizations 
and in Ethics committees for clinical trials. On the other 
hand, in Italy, CPOs participation is of similar degree in all 
aspects of health policy decision-making. It is noteworthy 
that the median value in all items included in the tool is 
below the midpoint in both countries, indicating overall low 
levels of CPOs participation in health policy. Similarly, in 
France the impact of participation was found to be higher in 
reforms or key decisions in health policy and in participation 
in panels/workshops held at the Ministry of Health or other 
health-related organisations. On the other hand, in Italy, the 
strongest impact was observed with respect to participation 
in panels/workshops in other important health related 
organizations. It is noteworthy that in both countries, the 
majority of participants have evaluated as absent-to-low the 
impact described in germane items. 
When CPOs participation was compared between the 2 
countries, converging data substantiate that levels of patient 
participation are higher in France than in Italy. In particular, 
France has demonstrated higher levels of participation in 
both item and scale analysis; while the impact of participation 
was also found to be greater. In addition, when the results 
regarding the type of participation were taken into account, 
the main type of participation was found to be “consultant” 
in France, as compared to “observed” in Italy. The differences 
between the 2 countries can be interpreted in light of the 
legislation and the preponderance of the patient-centred 
paradigm in the healthcare culture of each country.
The “Patients’ Rights and Quality of Care Act” in France (Act 
no. 2002-303) laid the foundations for promoting patients’ 
rights, patient empowerment and patient participation in 
health, facilitating their representation on a high policy level. 
At the same time, it paved the way for the establishment of 
specific guidelines and procedures for involving patients in 
different facets of health policy decision-making.44 On the 
contrary, in Italy there has been no specific legislation for 
patient participation and empowerment; even though general 
legislation for safeguarding patients’ rights does exist. In 
addition, Italy is a decentralized country and hence health 
policy decision-making is carried out on a regional level. 
As a result of this, there is a wide variation among regions 
with respect to the legislation on patient participation 
in health policy decision-making.45 Although the shift 
from central to regional level confers a lot of advantages, 
mainly in terms of funding and accountability, it may also 
cause interregional differences in patients’ involvement. 
Table 4. Descriptive Statistics for the Impact of Participation Concerning HDI Items for Italy and France
  
Impact
France Italy  
P No. (%) No. (%)
In reforms or key decisions in health policy
Absent to low 45 (48.4) 75 (78.9) < .001a
Moderate 15 (16.1) 20 (21.1)
High/very high 33 (35.5) 0 (0.0)
In panels of experts or workshops held in the  Ministry of Health
Absent to low 42 (45.2) 65 (68.4) .004a
Moderate 39 (41.9) 20 (21.1)
High/very high 12 (12.9) 10 (10.5)
In panels or workshops in other important organizations pertinent to 
health
Absent to low 60 (64.5) 75 (78.9) .011a
Moderate 18 (19.4) 5 (5.3)
High/very high 15 (16.1) 15 (15.8)
In hospital boards
Absent to low 57 (61.3) 75 (78.9) .010b
Moderate 33 (35.5) 20 (21.1)
High/very high 3 (3.2) 0 (0.0)
In Ethics Committees for clinical trials
Absent to low 60 (64.5) 80 (84.2) < .001b
Moderate 24 (25.8) 15 (15.8)
High/very high 9 (9.7) 0 (0.0)
In health technology assessment procedures for the scientific evaluation 
of new treatments & methods
Absent to low 84 (90.3) 80 (84.2) .495b
Moderate 6 (6.5) 10 (10.5)
High/very high 3 (3.2) 5 (5.3)
In health technology assessment procedures for the economic evaluation 
of new treatments & methods
Absent to low 69 (74.2) 70 (73.7) .076b
Moderate 24 (25.8) 20 (21.1)
High/very high 0 (0.0) 5 (5.3)
In the national parliament during decision-making for important health 
policies/legislation
Absent to low 69 (74.2) 70 (73.7) .246b
Moderate 21 (22.6) 25 (26.3)
High/very high 3 (3.2) 0 (0.0)  
Abbreviation: HDI, Health Democracy Index.
a Pearson chi-square test; b Fisher exact test.
Souliotis et al
International Journal of Health Policy and Management, 2018, 7(1), 48–58 55
Concomitantly, it has been argued that a highly decentralized 
system can substantially attenuate the influence of health 
patient organizations by diluting their capacity and diffusing 
further their limited resources.46 Apart from legislation and 
the configuration of the healthcare system, France has a 
long history in patient empowerment, especially due to the 
emergence of 2 generations of AIDS associations striving to 
achieve the active involvement of patients in health policy.47 It 
is noteworthy that in many countries, the fight against AIDS 
has been an exemplar of patients’ individual and collective 
efforts to participate in health and healthcare.47
It is evident that patients’ participation in health policy decision-
making is facilitated by the existence of relevant legislative 
provisions.3,48 The Council of Europe clearly stipulates that 
patient associations should be aided to participate “in the 
development of policies and programs on patient safety on all 
appropriate levels.”49 Accordingly, European countries should 
develop appropriate legislation and procedures in order to 
support patient involvement. Findings from the present study 
have revealed that patient participation is fostered by increased 
levels of knowledge about the healthcare system itself and 
reimbursement issues. This suggests that European countries 
should enhance patient involvement by implementing 
interventions on various levels.50 To raise awareness and 
promote patient empowerment, a number of European 
countries have developed relevant laws and regulations; 
while they have organized public campaigns. Most countries 
have established governmental and nongovernmental 
organizations and have adopted a “top-down” approach to 
support patient participation in health decision-making.17,51 
For instance, countries such as Australia, Canada, and the 
United Kingdom have established state and regional health 
councils, while they have developed initiatives to upgrade the 
role of patients in health policy decision-making.17,52-55 In the 
United States, participatory decision-making models have 
been developed to reinforce patient involvement. These in 
turn allow individuals to interact with health authorities so 
as to jointly formulate legislation and interventions in health 
Table 5. Comparisons Between France and Italy With Regard to the HDI Score
France Italy
HDI score
No. (%) Median (IQR) P No. (%) Median (IQR) P
How would you rate your familiarity with the disease?
 Very low to moderate 6 (7.7) 21 (21-21) .380a 55 (64.7) 9 (9-17) .764a
 High/very high 72 (92.3) 25.5 (20-27) 30 (35.3) 13 (10.5-14.5)
How would you rate your knowledge about treatment options?
 Very low to moderate 15 (19.2) 21 (19-22) .041a 55 (64.7) 9 (9-14) .036a
 High/very high 63 (80.8) 26 (20-27) 30 (35.3) 13.5 (10.5-23.5)
How would you rate your knowledge about your country healthcare 
system? 
 Very low to moderate 18 (26.1) 20 (16-21) .001a 55 (68.8) 9 (9-14) < .001a
 High/very high 51 (73.9) 25.5 (20-28) 25 (31.3) 23.5 (15-32)
How would you rate your knowledge about your country drug 
reimbursement processes?
 Very low to moderate 15 (19.2) 22 (20-26) .373a 65 (76.5) 9 (9-14) < .001a
 High/very high 63 (80.8) 25.5 (20-27) 20 (23.5) 15 (12-32)
Overall how would you rate the degree of collaboration of your 
organization with other patient organization of the same or other disease 
area?
 Absent to low 27 (29.0) 25 (22-26) .472a 40 (42.1) 9 (9-9) < .001a
 Moderate to very high 66 (71.0) 21.5 (20-27) 55 (57.9) 17 (14-32)
Is there an umbrella Patient Organization to represent all patients or 
different organizations in your country?
 No 63 (67.7) 26 (21-27) .006a 55 (57.9) 9 (9-14) .004a
 Yes 30 (32.3) 20.5 (19.5-22.5) 40 (42.1) 15 (12-32)
Is yοur patient organizatiοn a member οf an umbrella organizatiοn that 
represents yοu at a national policy-/decision-making level? 
No, there is no relevant federation/umbrella organization in my country 12 (12.9) 25 (16-35) < .001b 25 (26.3) 9 (9-17) .017b
No, my patient organization is not a member of a federation/umbrella 
organization
33 (35.5) 20 (19-22) 20 (21.1) 11.5 (9-14)
Yes 45 (48.4) 27 (21-27) 45 (47.4) 15 (12-32)
Does your patient organization collaborate with other patient 
organizations on a national policy-/decision-making level? 
 No 21 (22.6) 19 (17.5-20.5) < .001a 30 (31.6) 9 (9-17) .071a
 Yes 72 (77.4) 25 (21-27) 65 (68.4) 14 (9-32)
Abbreviation: HDI, Health Democracy Index.
aMann-Whitney test; bKruskal-Wallis test.
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related issues.56,57 A similar initiative in France resulted in 
a bill promoting a more democratic environment in health 
(“démocratie sanitaire”) through patient participation.58 The 
patients’ role was upgraded to include official opportunities 
wherein the individuals can equally contribute to and 
influenced decisions, policies and healthcare strategies.58 
In the United Kingdom, the commitment of the National 
Institute for Health and Care Excellence (NICE) to patient 
and public involvement in health policy decision-making is 
reflected on its key principles. The NICE has also developed 
relevant guidelines for empowering different groups of 
patients as well as for supporting organizations to participate 
in decisions and programs pertinent to health.59 
On the pan-European level, the “European Charter of 
Patients’ Rights” clearly states that patients have the right to 
participate in health policy-making.60 Likewise, according 
to the “Ljubljana Charter on Reforming Health Care in 
Europe”61 patients have the right to participate in shared 
decision-making on an equal basis and contribute to all 
relevant procedures that affect population health. Lastly, the 
Council of Europe suggests that patient empowerment should 
be an area of high priority.62
Strengths and Limitations of the Study
The main strength of the present study pertains to the good 
psychometric properties of the HDI and the provision of 
evidence on CPOs participation in Italy and France. The 
good psychometric properties of the HDI suggest that 
the tool can be used effectively to detect different degrees 
of patient participation and its impact. Item drafting and 
selection occurred through a thorough and rigorous process. 
Concomitantly, the assessment of the CPOs participation in 
health policy decision-making processes in Italy and France 
provides evidence for the CPOs’ contribution to health policy 
on a national level, highlighting in this way the needs and 
deficiencies that should be addressed in order to increase 
their capacity to impact health programs and policies.
Apart from its strengths, the study has also certain limitations. 
Even though the development and psychometric testing of the 
HDI was based on a rigorous process, its concurrent validity 
could not have been examined, as there is no gold standard 
for assessing patient participation on a meso/macro level. 
Moreover, due to the fact that there is no sampling frame for 
CPOs in EU, different strategies for identifying CPOS and 
recruiting participants were employed in order to minimize 
sampling bias. Additionally, CPOs that did not respond to the 
emails, were contacted multiple times over the phone in order 
to ensure participation. In spite of the versatile and consistent 
efforts to include as many CPOs as possible, the response rate 
is low, with the most visible and active CPOs being included 
into the sample. As a corollary of this, one cannot rule out 
the possibility of selection bias, with those CPOs refusing to 
take part in the study, not responding, to have lower levels 
of participation in health policy as compared to the CPOs 
that agreed to take part. Nonetheless, as response rates are 
similar in both countries, it is unlikely that selection bias may 
explain the differences observed between the 2 countries. 
Furthermore, as there was no sampling frame for the study, 
the sample could not have been random nor representative 
of the population. As a result of this and in conjunction with 
the low response rates, findings cannot be generalized to all 
members of CPOs in both countries. It also merits noting 
that information about the capacity of CPOs was not gleaned 
(eg, number of members, years since establishment), as the 
questionnaire was already time-consuming for responders 
and the particular questions may have been confusing. For 
example upon designing the study, the research team could 
not easily decide on which is more important, the number 
of a CPO’s members is more influential or the number 
of its active members. Similarly, “years since the CPO’s 
establishment” may have not been a useful proxy of its level of 
activity. Nonetheless, a future study should include this type 
of questions in its design to ensure taking into consideration 
these variables as well. 
The determinants for CPOs participation was not explored in 
depth; however, a follow-up report focusing on the individual 
and collective correlates of CPOs participation in both 
countries will be prepared.
Suggestions for Further Research
More studies are needed in order to understand the factors 
that facilitate and hinder high participation of CPOs in health 
policy, in different countries with different legal frameworks 
and healthcare systems. 
It is anticipated that the HDI will allow us to compare and 
contrast the degree of patient organization participation 
in decision-making in various countries and to set policy 
priorities in place. Moreover, the HDI can be used to evaluate 
the effectiveness of different programs aiming to improve 
patient participation in health decision-making on a meso/
macro level. At the same time, it may contribute to advocacy 
actions by shaping recommendations for enhancing patient 
empowerment and optimizing patient involvement in 
decision-making processes. 
Findings from ensuing national and international studies may 
lead to the development of a roadmap with the necessary steps 
needed so that patient organizations can establish a central 
position in decision-making processes in Europe.
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